Latest filings (excl ownership)
6-K/A
Extraordinary General Meeting of Shareholders
21 Mar 24
6-K
Extraordinary General Meeting of Shareholders
21 Mar 24
6-K
XTL To Aquire The Social Proxy
20 Mar 24
6-K
Report of Foreign Private Issuer
15 Nov 23
6-K
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
20 Oct 23
6-K
Report of Foreign Private Issuer
10 Aug 23
6-K
Report of Foreign Private Issuer
16 May 23
20-F
2022 FY
Annual report (foreign)
22 Mar 23
6-K
Current report (foreign)
2 Mar 23
6-K
Current report (foreign)
23 Feb 23
6-K/A
Annual General Meeting of Shareholders
1 Feb 23
6-K
Annual General Meeting of Shareholders
20 Jan 23
6-K
Report of Foreign Private Issuer
29 Nov 22
6-K
Condensed Interim Unaudited Consolidated Financial Statements
24 Aug 22
6-K
Report of Foreign Private Issuer
1 Jun 22
20-F
2021 FY
Annual report (foreign)
30 Mar 22
6-K
Current report (foreign)
26 Jan 22
6-K
Current report (foreign)
19 Jan 22
6-K
Annual General Meeting of Shareholders
16 Dec 21
6-K
Report of Foreign Private Issuer
24 Nov 21
6-K
Report of Foreign Private Issuer
24 Aug 21
424B3
Prospectus supplement
9 Jun 21
EFFECT
Notice of effectiveness
8 Jun 21
POS AM
Prospectus update (post-effective amendment)
2 Jun 21
6-K
Report of Foreign Private Issuer
19 May 21
20-F/A
2020 FY
Annual report (foreign) (amended)
19 May 21
6-K
Report of Foreign Private Issuer
19 May 21
6-K
Report of Foreign Private Issuer
5 Apr 21
6-K
Report of Foreign Private Issuer
29 Mar 21
20-F
2020 FY
Annual report (foreign)
15 Mar 21
6-K
Extraordinary General Meeting of Shareholders
22 Feb 21
6-K
Report of Foreign Private Issuer
7 Jan 21
6-K
Report of Foreign Private Issuer
31 Dec 20
6-K
Annual General Meeting of Shareholders
25 Nov 20
6-K
Report of Foreign Private Issuer
12 Nov 20
6-K
Report of Foreign Private Issuer
24 Aug 20
6-K
Report of Foreign Private Issuer
7 Jul 20
6-K
Report of Foreign Private Issuer
30 Jun 20
6-K
Report of Foreign Private Issuer
27 May 20
6-K
Extraordinary General Meeting of Shareholders
26 May 20